XSHE
000790
Market cap409mUSD
Oct 09, Last price
4.44CNY
1D
1.14%
1Q
20.33%
Jan 2017
-51.79%
Name
Chengdu Huasun Technology Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chengdu Huasun Technology Group Inc., Ltd., established in 1998, is a diversified enterprise operating from Chengdu, China. The company's core activities span both the pharmaceutical sector and the steel structure industry. In its pharmaceutical division, the company specializes in the manufacturing and distribution of various medicines, including modern and traditional Chinese remedies, as well as chemical pharmaceuticals. Additionally, it dedicates resources to the research, development, production, and marketing of biological products and advanced biotechnology drugs, particularly those targeting cardiovascular and cerebrovascular conditions. Beyond healthcare, Chengdu Huasun is also a prominent provider of comprehensive services for steel structure buildings. This includes the design, fabrication, installation, and maintenance of such constructions. The company's name was officially changed in April 2020, transitioning from its previous identity as Chengdu Taihe Health Technology Group Inc., Ltd.
Key people
Mingliang Huang
Chairman of the Board · since 2024
Jun Li
Chief Financial Officer, Vice President · since 2024
Gang Song
Vice President · since 2023
Yanling Huang
Director · since 2020
Hai Lan
Director · since 2023
Ping Ouyang
Director · since 2020
Duoxue Wang
Vice President, Director · since 2023
Ping Yang
Director · since 2023
Xudong Chen
Independent Director · since 2023
Daowei Mao
Independent Director · since 2023
Chaoxi Zhu
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||